XML 40 R26.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Revenue from Contracts with Customers (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2022
Schedule of Contract Assets and Contract Liabilities | Total contract assets at September 30, 2022 were as follows:
(In thousands) |  | Contract Assets |
Contract assets at December 31, 2021 |  | $ | 13,363 |
Additions |  |  | 30,215 |
Transferred to receivables, net |  |  | (33,473 | )
Contract assets at September 30, 2022 |  | $ | 10,105 |
Total contract liabilities at September 30, 2022 were as follows:
(In thousands) |  | Contract Liabilities |
Contract liabilities at December 31, 2021 |  | $ | 17,830 |
Additions |  |  | 2,595 |
Amounts recognized into revenue |  |  | (5,402 | )
Amounts recognized into other (expense) income, net |  |  | (6,384 | )
Contract liabilities at September 30, 2022 |  | $ | 8,639 |
Product sales, net |
Schedule of Disaggregation of Revenues | During the three and nine months ended September 30, 2022 and 2021, the Company recorded product sales, net, as follows:
|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
(In thousands) |  | 2022 |  |  | 2021 |  |  | 2022 |  |  | 2021 |
VIVITROL |  | $ | 96,534 |  |  | $ | 88,864 |  |  | $ | 277,493 |  |  | $ | 251,815 |
ARISTADA and ARISTADA INITIO |  |  | 75,719 |  |  |  | 68,873 |  |  |  | 222,826 |  |  |  | 196,693 |
LYBALVI |  |  | 27,127 |  |  |  | — |  |  |  | 61,116 |  |  |  | — |
Total product sales, net |  | $ | 199,380 |  |  | $ | 157,737 |  |  | $ | 561,435 |  |  | $ | 448,508 |
Manufacturing and royalty revenues |
Schedule of Disaggregation of Revenues | During the three and nine months ended September 30, 2022 and 2021, the Company recorded manufacturing and royalty revenues as follows:
|  | Three Months Ended September 30, 2022 |  |  | Nine Months Ended September 30, 2022 |
(In thousands) |  | Manufacturing Revenue |  |  | Royalty Revenue |  |  | Total |  |  | Manufacturing Revenue |  |  | Royalty Revenue |  |  | Total |
Long-acting INVEGA products(1) |  | $ | — |  |  | $ | 26,737 |  |  | $ | 26,737 |  |  | $ | — |  |  | $ | 90,439 |  |  | $ | 90,439 |
VUMERITY |  |  | 5,584 |  |  |  | 20,666 |  |  |  | 26,250 |  |  |  | 22,629 |  |  |  | 60,386 |  |  |  | 83,015 |
RISPERDAL CONSTA |  |  | 8,380 |  |  |  | 1,848 |  |  |  | 10,228 |  |  |  | 32,529 |  |  |  | 5,516 |  |  |  | 38,045 |
Other |  |  | 3,265 |  |  |  | (13,539 | ) |  |  | (10,274 | ) |  |  | 26,472 |  |  |  | 5,466 |  |  |  | 31,938 |
|  | $ | 17,229 |  |  | $ | 35,712 |  |  | $ | 52,941 |  |  | $ | 81,630 |  |  | $ | 161,807 |  |  | $ | 243,437 |
|  | Three Months Ended September 30, 2021 |  |  | Nine Months Ended September 30, 2021 |
(In thousands) |  | Manufacturing Revenue |  |  | Royalty Revenue |  |  | Total |  |  | Manufacturing Revenue |  |  | Royalty Revenue |  |  | Total |
Long-acting INVEGA products(1) |  | $ | — |  |  | $ | 79,323 |  |  | $ | 79,323 |  |  | $ | — |  |  | $ | 221,965 |  |  | $ | 221,965 |
VUMERITY |  |  | 8,499 |  |  |  | 18,250 |  |  |  | 26,749 |  |  |  | 17,671 |  |  |  | 42,866 |  |  |  | 60,537 |
RISPERDAL CONSTA |  |  | 8,725 |  |  |  | 2,245 |  |  |  | 10,970 |  |  |  | 31,411 |  |  |  | 8,172 |  |  |  | 39,583 |
Other |  |  | 6,762 |  |  |  | 12,490 |  |  |  | 19,252 |  |  |  | 29,282 |  |  |  | 47,068 |  |  |  | 76,350 |
|  | $ | 23,986 |  |  | $ | 112,308 |  |  | $ | 136,294 |  |  | $ | 78,364 |  |  | $ | 320,071 |  |  | $ | 398,435 |
(1) “Long-acting INVEGA products”: INVEGA SUSTENNA/XEPLION (paliperidone palmitate), INVEGA TRINZA/TREVICTA (paliperidone palmitate) and INVEGA HAFYERA/BYANNLI (paliperidone palmitate)

X
- Definition Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_ProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=alks_ManufacturedProductAndRoyaltyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |